Perimeter Medical Imaging AI, Inc. (PYNKF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PYNKF steht fuer Perimeter Medical Imaging AI, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erreicht einen hohen Ueberzeugungsscore von 73/100 ueber fundamentale, technische und Stimmungsfaktoren.
Zuletzt analysiert: 16. März 2026Perimeter Medical Imaging AI, Inc. (PYNKF) Gesundheitswesen & Pipeline-Uebersicht
Perimeter Medical Imaging AI, Inc. is a medical technology company specializing in advanced imaging tools, including OCT systems and AI-driven image analysis, for real-time surgical margin visualization. Their focus is on improving surgical precision and patient outcomes, particularly in cancer surgeries, by reducing the likelihood of repeat procedures. The company operates within the medical devices sector.
Investmentthese
Perimeter Medical Imaging AI, Inc. presents a compelling investment thesis centered on its innovative OCT imaging technology and AI-powered image analysis platform. The company's solutions address a critical need in surgical oncology: the accurate and real-time assessment of surgical margins. With a market capitalization of $0.04 billion, PYNKF operates in the medical devices sector, where precision and efficiency are paramount. The company's growth catalysts include expanding adoption of its ImgAssist AI technology and increasing sales of its OCT imaging systems. Key value drivers include the potential to reduce repeat surgeries, improve patient outcomes, and streamline surgical workflows. However, the company's negative profit margin of -736.5% and reliance on OTC markets pose significant risks that must be considered.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.04 billion indicates a small-cap company with potential for growth but also higher volatility.
- Negative P/E ratio of -2.29 reflects the company's current lack of profitability.
- Gross margin of 51.1% demonstrates the company's ability to generate revenue above the direct costs of its products.
- Profit margin of -736.5% highlights significant operational inefficiencies or high operating expenses.
- Beta of 1.56 suggests the stock is more volatile than the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative OCT imaging technology
- AI-powered image analysis platform (ImgAssist)
- Potential to improve surgical outcomes and reduce repeat surgeries
- Proprietary image libraries and consumable specimen containers
Schwaechen
- Negative profit margin (-736.5%)
- Reliance on OTC markets
- Limited market capitalization ($0.04 billion)
- Dependence on a single industry (surgical oncology)
Katalysatoren
- Ongoing: Expansion of the ImgAssist AI platform into new hospitals and cancer centers.
- Upcoming: Potential regulatory approvals for new applications of the OCT imaging system.
- Ongoing: Strategic partnerships with leading medical device companies to expand market reach.
- Upcoming: Publication of clinical trial results demonstrating the effectiveness of Perimeter Medical's technologies.
- Ongoing: Increasing adoption of OCT imaging systems in surgical oncology.
Risiken
- Potential: Competition from established medical device companies with greater resources.
- Ongoing: Regulatory hurdles and approval processes for new products and applications.
- Potential: Technological obsolescence and the emergence of competing imaging technologies.
- Ongoing: Economic downturns and healthcare spending cuts impacting hospital budgets.
- Potential: Limited financial resources and the need for additional funding to support growth.
Wachstumschancen
- Expansion of ImgAssist AI Technology: Perimeter Medical's ImgAssist AI platform represents a significant growth opportunity. By enhancing the efficiency of image review and providing real-time margin visualization, ImgAssist can improve surgical outcomes and reduce the need for repeat surgeries. The market for AI in healthcare is projected to reach $34 billion by 2025, offering a substantial addressable market for Perimeter Medical. The company can leverage its existing OCT systems to drive adoption of ImgAssist, creating a recurring revenue stream through software subscriptions and licensing agreements.
- Increased Adoption of OCT Imaging Systems: The company's OCT imaging systems provide clinicians with high-resolution, real-time visualization of microscopic tissue structures. As demand for more precise surgical techniques grows, the adoption of OCT imaging systems is expected to increase. The global optical coherence tomography market is projected to reach $1.9 billion by 2027. Perimeter Medical can capitalize on this trend by expanding its sales and marketing efforts, targeting hospitals and cancer surgery centers.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with leading hospitals, research institutions, and medical device companies can accelerate the development and commercialization of Perimeter Medical's technologies. Collaborations can provide access to new markets, funding, and expertise. For example, partnering with a major cancer center could facilitate clinical trials and validation of the company's products, leading to increased adoption and market penetration.
- Geographic Expansion: Perimeter Medical can expand its geographic reach by targeting new markets in Europe, Asia, and other regions. International expansion requires adapting products to local regulations and healthcare systems, but it can significantly increase the company's revenue potential. The global medical device market is expected to reach $600 billion by 2025, with significant growth opportunities in emerging markets.
- Development of New Applications: Perimeter Medical can explore new applications for its OCT imaging and AI technologies beyond surgical oncology. For example, the company could develop solutions for dermatology, ophthalmology, or other medical specialties. Expanding into new therapeutic areas can diversify the company's revenue streams and reduce its reliance on a single market. The market for medical imaging in dermatology is projected to reach $1.5 billion by 2028, representing a potential growth opportunity for Perimeter Medical.
Chancen
- Expansion of ImgAssist AI technology
- Increased adoption of OCT imaging systems
- Strategic partnerships and collaborations
- Geographic expansion into new markets
Risiken
- Competition from established medical device companies
- Regulatory hurdles and approval processes
- Technological obsolescence
- Economic downturns and healthcare spending cuts
Wettbewerbsvorteile
- Proprietary OCT imaging technology provides a competitive advantage in real-time tissue visualization.
- ImgAssist AI platform enhances the efficiency of image review and improves surgical outcomes.
- Established relationships with hospitals and cancer surgery centers create barriers to entry for competitors.
- Proprietary image libraries and consumable specimen containers generate recurring revenue streams.
Ueber PYNKF
Founded in 2013 and headquartered in Toronto, Canada, Perimeter Medical Imaging AI, Inc. is a medical technology company focused on developing and commercializing advanced imaging tools for use during surgical procedures. The company's core technology is an optical coherence tomography (OCT) imaging system that provides surgeons, radiologists, and pathologists with high-resolution, real-time visualization of microscopic tissue structures. This system allows clinicians to examine tissue down to a depth of 2 mm, offering detailed cross-sectional images that can aid in margin assessment during surgery. The OCT imaging system comprises the S-series OCT, B-series OCT, and an OCT imaging console. In addition to its OCT technology, Perimeter Medical Imaging AI offers ImgAssist, an artificial intelligence (AI) platform designed to enhance the efficiency of image review. When used with Perimeter OCT, ImgAssist provides physicians with real-time margin visualization and assessment capabilities, potentially improving surgical outcomes and reducing the need for additional surgeries. The company also provides proprietary image libraries and consumable specimen containers to hospitals and cancer surgery centers, creating a comprehensive solution for intraoperative tissue imaging. Perimeter Medical Imaging AI aims to transform cancer surgery by providing tools that enable more precise and complete tumor removal.
Was das Unternehmen tut
- Develop and commercialize optical coherence tomography (OCT) imaging systems for real-time tissue visualization.
- Provide surgeons, radiologists, and pathologists with high-resolution microscopic images during clinical procedures.
- Offer the ImgAssist AI platform to enhance image review and aid in margin assessment during surgery.
- Supply proprietary image libraries and consumable specimen containers to hospitals and cancer surgery centers.
- Enable more precise and complete tumor removal during cancer surgeries.
- Reduce the likelihood of repeat surgeries through improved margin visualization.
Geschaeftsmodell
- Sales of OCT imaging systems to hospitals and cancer surgery centers.
- Subscription fees for the ImgAssist AI platform.
- Revenue from the sale of proprietary image libraries and consumable specimen containers.
- Potential licensing agreements for its OCT and AI technologies.
Branchenkontext
Perimeter Medical Imaging AI operates within the medical devices industry, specifically targeting the surgical oncology market. The industry is characterized by continuous innovation in imaging technologies and a growing demand for minimally invasive surgical techniques. Companies like ALRTF (Alerion Technologies), ASAPF (Asante Solutions), EMITF (Emtora Biosciences), GBLP (Global Partners LP), and GTHP (Gelesis Holdings) represent the competitive landscape. The increasing prevalence of cancer and the drive to improve surgical outcomes are key market trends driving growth in this sector. Perimeter Medical's focus on real-time margin assessment positions it to capitalize on the demand for more precise and effective surgical tools.
Wichtige Kunden
- Hospitals
- Cancer surgery centers
- Surgeons
- Radiologists
- Pathologists
Finanzdaten
Chart & Info
Perimeter Medical Imaging AI, Inc. (PYNKF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Perimeter Medical Imaging AI's 'Claire' Becomes First FDA-approved AI-Enabled Imaging Device for Breast Cancer Surgery
prnewswire.com · 3. März 2026
-
Perimeter Announces Grant and Cancellation of Stock Options
prnewswire.com · 17. Feb. 2026
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer PYNKF.
Kursziele
Wall-Street-Kurszielanalyse fuer PYNKF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von PYNKF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Adrian Mendes
CEO
Adrian Mendes is the Chief Executive Officer of Perimeter Medical Imaging AI, Inc. His background includes extensive experience in the medical device industry, with a focus on commercializing innovative technologies. He has a proven track record of leading teams and driving growth in the healthcare sector. Mendes is responsible for overseeing the company's strategic direction, product development, and commercialization efforts. He manages a team of 65 employees.
Erfolgsbilanz: Under Adrian Mendes' leadership, Perimeter Medical Imaging AI has focused on expanding the market reach of its OCT imaging systems and ImgAssist AI platform. Key milestones include securing regulatory approvals for its products and establishing partnerships with leading hospitals and cancer centers. He has overseen the company's efforts to improve surgical outcomes and reduce the need for repeat surgeries through the adoption of its technologies.
PYNKF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Perimeter Medical Imaging AI, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies typically have less stringent listing requirements, resulting in increased risk for investors due to potential lack of transparency and liquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency
- Lower trading volume and liquidity compared to major exchanges
- Potential for wider bid-ask spreads and price volatility
- Increased regulatory scrutiny and compliance risks
- Higher risk of fraud or manipulation due to less stringent listing requirements
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and compliance history.
- Evaluate the company's cash flow and financial stability.
- Check for any legal or regulatory actions against the company.
- Consult with a financial advisor before making any investment decisions.
- Development and commercialization of innovative medical imaging technologies
- Focus on improving surgical outcomes and reducing repeat surgeries
- Partnerships with hospitals and cancer surgery centers
- Management team with experience in the medical device industry
Haeufige Fragen zu PYNKF
What are the key factors to evaluate for PYNKF?
Perimeter Medical Imaging AI, Inc. (PYNKF) currently holds an AI score of 73/100, indicating high score. Key strength: Innovative OCT imaging technology. Primary risk to monitor: Potential: Competition from established medical device companies with greater resources.. This is not financial advice.
How frequently does PYNKF data refresh on this page?
PYNKF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PYNKF's recent stock price performance?
Recent price movement in Perimeter Medical Imaging AI, Inc. (PYNKF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative OCT imaging technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PYNKF overvalued or undervalued right now?
Determining whether Perimeter Medical Imaging AI, Inc. (PYNKF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PYNKF?
Before investing in Perimeter Medical Imaging AI, Inc. (PYNKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PYNKF to a portfolio?
Potential reasons to consider Perimeter Medical Imaging AI, Inc. (PYNKF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative OCT imaging technology. Additionally: AI-powered image analysis platform (ImgAssist). The AI-driven MoonshotScore of 73/100 reflects strong quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of PYNKF?
Yes, most major brokerages offer fractional shares of Perimeter Medical Imaging AI, Inc. (PYNKF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track PYNKF's earnings and financial reports?
Perimeter Medical Imaging AI, Inc. (PYNKF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for PYNKF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is based on available information and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights in the future.